Eleni Gavriilaki – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Thu, 26 Aug 2021 17:27:49 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Eleni Gavriilaki – VJRegenMed https://mirror.vjregenmed.com 32 32 Complement inhibition for the treatment of TA-TMA https://mirror.vjregenmed.com/video/4_get6p6qm4-complement-inhibition-for-the-treatment-of-ta-tma/ Thu, 13 May 2021 17:34:10 +0000 http://13.40.107.223/video/4_get6p6qm4-complement-inhibition-for-the-treatment-of-ta-tma/ Eleni Gavriilaki, MD, PhD, George Papanikolaou Hospital, Thessaloniki, Greece, discusses the role of complement activation in the pathophysiology of transplant-associated thrombotic microangiopathy (TA-TMA), a severe complication of hematopoietic stem cell transplantation (HSCT), and research into complement inhibitors such as eculizumab for the treatment of patients with TA-TMA. At ASGCT 2021, Dr Gavriilaki presented research into functional assays for the diagnosis of TA-TMA, as well as therapeutic data evaluating complement inhibition, which has resulted in improved survival in selected TA-TMA patient populations. The MASP-2 inhibitor narsoplimab is also currently being investigated in clinical trials for TA-TMA. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

]]>